Australia's most trusted
source of pharma news
Sunday, 18 May 2025
Posted 16 July 2024 AM
A changing of the guard of the world's top selling drugs is just around the corner with two rival companies slated to monopolise the leader board, raking in more than US$100 billion in combined sales a year.
According to the latest report from analytics firm Evaluate, half of the top 10 selling prescription drugs in 2030 will be treatments for metabolic diseases, such as obesity and diabetes, sponsored by Novo Nordisk and Eli Lilly.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.